1. Home
  2. PTAC vs SLGL Comparison

PTAC vs SLGL Comparison

Compare PTAC & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PTAC

Patriot Acquisition Corp. Class A Ordinary Shares

N/A

Current Price

$10.02

Market Cap

218.8M

Sector

Finance

ML Signal

N/A

Logo Sol-Gel Technologies Ltd.

SLGL

Sol-Gel Technologies Ltd.

SELL

Current Price

$55.02

Market Cap

180.5M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
PTAC
SLGL
Founded
2025
1997
Country
United States
Israel
Employees
N/A
N/A
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
218.8M
180.5M
IPO Year
2026
2016

Fundamental Metrics

Financial Performance
Metric
PTAC
SLGL
Price
$10.02
$55.02
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
★ $155.50
AVG Volume (30 Days)
★ 58.2K
29.2K
Earning Date
N/A
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.88
$34.47
52 Week High
$10.06
$97.97

Technical Indicators

Market Signals
Indicator
PTAC
SLGL
Relative Strength Index (RSI) 58.62 33.38
Support Level N/A N/A
Resistance Level $10.06 $81.68
Average True Range (ATR) 0.01 4.16
MACD 0.01 -0.73
Stochastic Oscillator 69.31 25.24

Price Performance

Historical Comparison
PTAC
SLGL

About PTAC Patriot Acquisition Corp. Class A Ordinary Shares

Patriot Acquisition Corp is a blank check company.

About SLGL Sol-Gel Technologies Ltd.

Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.

Share on Social Networks: